A 6-year-old girl with autism spectrum disorder (diagnosed at age 4) is referred to the child psychiatry clinic for behavioural management. Her parents report that she has severe tantrums lasting 20–30 minutes when transitions occur (e.g., leaving home, changing activities). She also has significant sensory sensitivities — she covers her ears at loud sounds and refuses to wear certain clothing textures. She has a restricted diet, eating only 5–6 specific foods. Her communication consists of echolalia and scripted phrases from television shows, with minimal spontaneous speech. She has an IQ of 52 on formal testing. What is the most appropriate first-line pharmacological intervention for her severe behavioural dysregulation?

Explanation

## Pharmacological Management of Behavioural Dysregulation in ASD ### Evidence-Based First-Line Agent **Key Point:** Risperidone is the **only FDA-approved antipsychotic for irritability in autism spectrum disorder** and is the first-line pharmacological agent for severe behavioural dysregulation, including aggression, self-injury, and severe tantrums. ### Evidence Base for Risperidone in ASD | Feature | Evidence | | --- | --- | | **FDA Approval** | Approved for irritability associated with ASD in children 5–16 years (2006) | | **RCT Evidence** | RUPP Autism Network trial: risperidone superior to placebo for irritability | | **Effect Size** | Moderate to large effect on aggression, tantrums, self-injury | | **Dosing** | 0.5–6 mg/day (typically 1–3 mg/day in divided doses) | | **Onset** | Benefits visible within 2–4 weeks | **High-Yield:** Aripiprazole is also FDA-approved for ASD irritability and is an alternative first-line agent. Both are preferred over other antipsychotics due to better tolerability and evidence. ### Clinical Rationale for This Case This child has: - **Severe behavioural dysregulation** (tantrums lasting 20–30 minutes) - **Moderate-to-severe intellectual disability** (IQ 52) — increases risk of behavioural problems - **Sensory sensitivities and rigidity** contributing to distress and dysregulation - **Limited verbal communication** — cannot use verbal coping strategies Risperidone addresses the neurobiological basis of irritability in ASD (dopaminergic dysregulation) and is evidence-based for this presentation. ### Prerequisite Before Starting **Clinical Pearl:** Before initiating risperidone, obtain: 1. **Baseline metabolic panel** (glucose, lipids) 2. **Prolactin level** 3. **Weight and BMI** 4. **Baseline EPS assessment** (abnormal involuntary movement scale) 5. **ECG** (if family history of sudden cardiac death or QT prolongation) ### Monitoring During Treatment **Mnemonic: WEIGHT-METAB-EPS** — **W**eight gain (most common side effect), **E**xtrapyramidal symptoms, **I**ncrease in prolactin, **G**lucose/metabolic abnormalities, **H**ypertension; **M**etabolic panel q3–6 months, **E**CG if indicated, **T**riglycerides; **E**PS monitoring, **P**rolactin levels, **S**eizure risk (lower threshold in ASD). ### Behavioural Interventions (Essential Adjunct) **Warning:** Pharmacotherapy alone is insufficient. Concurrent behavioural strategies are mandatory: - Applied Behaviour Analysis (ABA) for tantrums - Visual schedules and social stories for transitions - Sensory integration therapy - Environmental modifications (reduce sensory triggers)